▲ +132.01% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Onconova Therapeutics in the last 3 months. The average price target is $1.52, with a high forecast of $2.00 and a low forecast of $1.25. The average price target represents a 132.01% upside from the last price of $0.65.
The current consensus among 4 contributing investment analysts is to hold stock in Onconova Therapeutics. This Hold consensus rating has held steady for over two years.
Onconova Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion Phase 1 trial is planned in the U.S. The company's product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.